Related Experiment Videos
[Selenium deficiency in patients with cardiovascular diseases and its correction with the drug "selena"]
Insights
Selenium deficiency is linked to heart disease. Supplementation with Selena improved selenium levels and reduced oxidative stress markers in patients with ischemic heart disease and dilated cardiomyopathy.
Area of Science:
- Biochemistry
- Cardiology
- Nutritional Science
Context:
- Investigated blood selenium levels, glutathione peroxidase (GPO) activity, and plasma lipid peroxides in patients with ischemic heart disease (IHD) and dilated cardiomyopathy (DCMP).
- Observed depressed GPO activity and elevated lipid peroxides in IHD and DCMP patients, correlating with lower blood selenium concentrations.
Purpose:
- To explore the role of selenium in the pathogenesis of IHD and DCMP.
- To evaluate the efficacy of selenium supplementation (300 micrograms daily from Selena) in patients with IHD and DCMP.
Summary:
- A one-month treatment with Selena significantly increased blood selenium concentrations by 71% in IHD and DCMP patients.
- This increase in selenium showed an inverse correlation with baseline selenium levels.
- Plasma malonic dialdehyde, a marker of lipid peroxidation, decreased by 17% following selenium supplementation.
Impact:
- Findings suggest selenium deficiency plays a role in the development of DCMP and IHD.
- Identifies potential candidates with selenium deficiency for therapeutic correction using Selena.
- Highlights the importance of selenium status in cardiovascular health and disease management.
Abstract:
Blood selenium concentrations, erythrocytic glutathione peroxidase (GPO) activity, and plasma lipid peroxides were investigated in patients with ischemic heart disease (IHD) and dilated cardiomyopathy (DCMP). Patients with IHD and DCMP displayed depressed activity of GPO with activation of lipid peroxides associated with lower blood selenium. The daily intake of 300 micrograms of selenium from Selena during a month treatment augmented selenium concentrations by 71% in IHD and DCMP patients. This augmentation showed an inverse correlation with primary plasma selenium concentrations. Plasma malonic dialdehyde levels decreased by 17%. The findings suggest that selenium is involved in the pathogenesis of DCMP and IHD, which may be a ground for selecting patients with selenium deficiency for its correction with Selena.